Published in Proc Natl Acad Sci U S A on March 01, 1981
Diversity of lipid-based polyene formulations and their behavior in biological systems. Eur J Clin Microbiol Infect Dis (1997) 0.96
Nanopharmaceuticals (part 1): products on the market. Int J Nanomedicine (2014) 0.95
Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model. Br J Cancer (1985) 0.93
In vivo biodistribution of a radiolabeled blood substitute: 99mTc-labeled liposome-encapsulated hemoglobin in an anesthetized rabbit. Proc Natl Acad Sci U S A (1991) 0.86
Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. Br J Cancer (1996) 0.84
An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation. Br J Cancer (1996) 0.81
Association of liposomes with the isolated perfused rabbit heart. Basic Res Cardiol (1983) 0.77
A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer (1973) 5.51
Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77
New aspects of liposomes. Biochim Biophys Acta (1976) 2.27
Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev (1976) 1.44
Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin. Biochem Pharmacol (1978) 1.11
Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. Cancer Treat Rep (1980) 1.03
Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res (1980) 1.02
Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res (1977) 1.01
Delayed and progressive myocardial lesions after adriamycin administration in the rabbit. Cancer Res (1976) 1.00
In vitro and in vivo studies with adriamycin liposomes. Biochem Biophys Res Commun (1979) 0.98
Subacute cardiotoxicity of adriamycin in the rat: biochemical and ultrastructural investigations. Lab Invest (1977) 0.93
Sudden death during doxorubicin administration. Cancer (1979) 0.92
Adriamycin-induced cardiac damage in the mouse: a small-animal model of cardiotoxicity. J Natl Cancer Inst (1975) 0.90
Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo. Cancer Res (1980) 0.88
Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia. Cancer Res (1979) 0.88
Mechanisms of reduction of antitumor drug toxicity by liposome encapsulation. Ann N Y Acad Sci (1978) 0.87
Affinity of adriamycin to phospholipids. A possible explanation for cardiac mitochondrial lesions. Biochem Biophys Res Commun (1976) 0.83
Ultrastructural alterations of atrial myocardium induced by adriamycin in chronically treated animals. Tumori (1978) 0.81
Liposomes as lysosomotropic carriers. Ann N Y Acad Sci (1978) 0.80
Experimental evaluation of anthracycline analogs. Cancer Treat Rep (1979) 0.79
Membrane actions of daunorubicin in mammalian erythrocytes. Res Commun Chem Pathol Pharmacol (1977) 0.78
In vitro and in vivo studies with adriamycin liposomes. Biochem Biophys Res Commun (1979) 0.98
Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes. Cancer Res (1983) 0.84
Attenuation of dermal toxicity of doxorubicin by liposome encapsulation. Cancer Treat Rep (1983) 0.77
Phospholipid prodrug inhibitors of the HIV protease. Antiviral activity and pharmacokinetics in rats. Biochem Pharmacol (1994) 0.75